COPENHAGEN, Denmark--(

丹麦哥本哈根--(

BUSINESS WIRE

商业热线

)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million. The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs, called ‘.

)--Orbis Medicines是口服大环化合物药物发现的领导者，今天宣布9000万欧元的a系列融资回合结束，使公司筹集的总金额达到1.16亿欧元。这些资金将支持Orbis“下一代口服大环药物管道”的开发。

n

n

Cycles.’ This financing was led by NEA (New Enterprise Associates) with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion. Morten Graugaard has been named the Chief Executive Officer of Orbis Medicines following nearly three years serving as Executive Chair of its Board of Directors.

周期。”此次融资由NEA（New Enterprise Associates）牵头，新投资者包括礼来公司（Eli Lilly and Company）、鸬鹚（Cormorant）、丹麦出口与投资基金（Export and Investment Fund of Denmark）以及创始投资者诺沃控股（Novo Holdings）和福比昂（Forbion）。MortenGraugaard在担任董事会执行主席近三年后，被任命为Orbis Medicines的首席执行官。

Mr. Graugaard brings more than 20 years of experience in life sciences including venture investing, R&D, business development, corporate development and strategy to Orbis’ leadership team..

。。

Orbis Medicines is focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties but historically have been challenging to develop as oral drugs. Orbis Medicines’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets to maximize value for patients..

Orbis Medicines专注于开创口服大环化合物药物发现的新时代。大环化合物是一大类多样的化合物，具有非常理想的治疗特性，但历史上一直难以开发为口服药物。Orbis Medicines的计划专注于重磅生物药物的高价值口服替代品，并以最大限度地为患者创造价值为目标。。

“

“

The support from this particular group of investors is further validation of the exemplary science and exciting potential of Orbis Medicines. The company is advancing the potential of macrocycles by developing orally available

这一特殊投资者群体的支持进一步验证了奥比斯药物的示范性科学和令人兴奋的潜力。该公司正在通过开发口服药物来提高大环化合物的潜力

n

n

Cycles — a format preferred by patients, physicians and healthcare systems, particularly for chronic diseases,” said Morten Graugaard, newly appointed Orbis CEO. “

Orbis新任首席执行官莫滕·格拉加德（MortenGraugaard）表示：“周期是患者、医生和医疗保健系统尤其是慢性病患者首选的一种形式。”。“”

The interest we have received demonstrates the market appetite for

我们收到的兴趣表明了市场对

n

n

Cycles as an oral approach to both validated biologic targets and targets undruggable by other modalities. We have a clear strategy for rapid value creation that leverages the unique capabilities of our

循环作为一种口服方法，用于验证生物靶标和其他方式无法治疗的靶标。我们有一个明确的快速价值创造战略，利用我们的独特功能

n

n

Gen platform and are excited to advance this important new class of drugs for patients.”

Gen平台，并很高兴为患者推进这一重要的新型药物。”

“

“

The Orbis Medicines team has impressed us with the data supporting

Orbis Medicines团队的数据支持给我们留下了深刻的印象

n

n

Gen, which we believe is the world’s leading discovery engine for oral macrocycle drugs. We are thrilled to support not only their journey to the clinic, but also their longer-term vision as a leader in their field,” said Ed Mathers, Partner, NEA. “

Gen，我们认为它是口服大环类药物的世界领先发现引擎。NEA合伙人埃德·马瑟斯（EdMathers）说：“我们很高兴不仅支持他们的诊所之旅，而且支持他们作为该领域领导者的长期愿景。”。“”

We congratulate Morten on his appointment as CEO after years of successfully guiding the company as Chair. He brings the depth of knowledge and expertise to lead Orbis through this crucial growth phase and deliver on the potential of

我们祝贺莫滕在多年成功指导公司担任主席后被任命为首席执行官。

n

n

Cycles.”

周期。”

About Orbis Medicines

关于Orbis Medicines

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its

Orbis Medicines开创了口服大环化合物药物发现的新时代。Its公司

n

n

Gen platform systematically delivers macrocycle candidates, termed

Gen平台系统地提供大环候选物，称为

n

n

Cycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis’ pipeline is initially focused on

周期。这些针对口服生物利用度进行了优化，这在历史上阻碍了这类多功能分子的治疗发展。Orbis的管道最初专注于

n

n

Cycle candidates against targets validated by blockbuster biologic drugs delivered by injection. In 2024, Orbis raised a EUR 26 million series seed round co-led by Novo Holdings and Forbion. Proof-of-concept of Orbis’ work has been published in

针对通过注射递送的重磅生物药物验证的靶标循环候选药物。2024年，Orbis在Novo Holdings和Forbion的共同领导下，筹集了2600万欧元的系列种子资金。

Nature Communications

自然通讯

and

和

Nature Chemical Biology

. The company is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit:

该公司位于丹麦哥本哈根和瑞士洛桑。有关更多信息，请访问：

www.orbismedicines.com

www.orbismedicines.com

About

关于

n

n

Gen and

发电机和

n

n

Cycles

周期

n

n

Gen is Orbis Medicines’ technology platform for generating

Gen是Orbis Medicines的技术平台

n

n

Cycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a “lab in a loop” system starting with hit finding libraries of 100 billion compounds. The highly automated chemistry-based .

。它由“循环实验室”系统中的多个专有集成元素组成，从1000亿化合物的命中发现库开始。高度自动化的化学基础。

n

n

Gen platform can synthesize and analyze up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning, creates an industry-leading platform that de-risks and accelerates development..

Gen平台可以在几周内合成和分析多达100000种不同的合成大环化合物，使公司能够发现具有正确特性的候选物，以实现口服给药和细胞内靶向。这些真实化合物产生的数据的规模和质量，再加上机器学习，创造了一个行业领先的平台，可以降低风险并加速发展。。